✦ LIBER ✦

Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12

✍ Scribed by Isamu Yokoe; Shinya Nishio; Hiroshi Sato; Hitomi Kobayashi

Publisher: Springer
Year: 2011
Tongue: English
Weight: 318 KB
Volume: 21
Category: Article
ISSN: 1439-7595
DOI: 10.1007/s10165-011-0474-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Direct comparison of treatment responses

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

✍ Merete Lund Hetland; Ib Jarle Christensen; Ulrik Tarp; Lene Dreyer; Annette Hans 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Comparison of the response to infliximab

Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register

✍ Kimme L. Hyrich; Deborah P. M. Symmons; Kath D. Watson; Alan J. Silman; British 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Abstract ## Objective To compare outcome at 6 months in unselected “real‐world” patients with rheumatoid arthritis treated with etanercept or infliximab as either monotherapy, cotherapy with methotrexate (MTX), or cotherapy with another disease‐modifying antirheumatic drug (DMARD). ## Methods